Quick Answer
AC Immune SA reported Research And Development Expense of $56.44 million for the year ending 2025.
- AC Immune SA showed a decrease of -9.8% in Research And Development Expense from 2024 to 2025.
- This data is from AC Immune SA's annual report (Form 10-K), filed with the SEC on March 13, 2026.
- XBRL data for this metric is available from 2015 to 2025 (11 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
- Quarterly values from 10-Q filings: Q1 2017: $7.45 million | Q2 2017: $6.84 million | Q3 2017: $8.20 million | Q4 2017: $10.18 million | Q1 2018: $10.07 million | Q2 2018: $10.53 million | Q3 2018: $11.55 million | Q4 2018: $12.13 million.
- Over the full 11 years of available data (2015 to 2025), AC Immune SA's Research And Development Expense has grown by 231.0%.
- Historical annual values: Fiscal year 2025: $56.44 million | Fiscal year 2024: $62.57 million | Fiscal year 2023: $54.61 million | Fiscal year 2022: $60.34 million | Fiscal year 2021: $62.28 million | Fiscal year 2020: $59.49 million | Fiscal year 2019: $50.43 million | Fiscal year 2018: $44.28 million | Fiscal year 2017: $32.66 million | Fiscal year 2016: $25.77 million | Fiscal year 2015: $17.05 million.
- Data sourced from SEC EDGAR public filings as of August 5, 2026.
Last verified: